Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus PRADAXA.
EDOXABAN vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
60 mg orally once daily
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
Clinical Note
moderateEdoxaban + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Benzydamine
"Edoxaban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateEdoxaban + Deferasirox
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category C
Category C
Anticoagulant
Anticoagulant
"The risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox."